Compare Moderna, Inc. (MRNA) vs Waste Management, Inc. (WM) Price & Performance

Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.

Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.

Waste Management (WM) trades at $208.83, showing minimal daily movement with a slight decline of 0.05%. The stock maintains strong profitability metrics including a 29.83% ROE and 11.12% net margin, though valuation ratios appear elevated with a P/E of 29.72. Recent earnings show mixed performance with two beats and one miss in the last three quarters. Technical indicators suggest a bullish overall signal despite bearish moving averages, with key support at $208 and resistance at $212.

WM demonstrates resilient fundamentals with steady revenue growth and strong cash flow generation, though elevated debt levels and tight liquidity present concerns. Analyst consensus remains positive with 54% buy ratings and no sell recommendations. The company's essential service business model provides defensive characteristics, but investors should monitor debt management and competitive pressures in the waste management sector.